Open AccessThe incidence and risk of cutaneous toxicities associated with dabrafenib in melanoma patients: a systematic review and meta-analysis
Author(s) -
Peng Chen,
Jiexin Lei
Publication year - 2020
Publication title -
european journal of hospital pharmacy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.313
H-Index - 14
eISSN - 2047-9964
pISSN - 2047-9956
DOI - 10.1136/ejhpharm-2020-002347
Subject(s) - dabrafenib , medicine , trametinib , rash , melanoma , incidence (geometry) , meta analysis , keratoacanthoma , dermatology , skin cancer , clinical trial , adverse effect , oncology , cancer , vemurafenib , basal cell , metastatic melanoma , cancer research , mapk/erk pathway , physics , kinase , optics , biology , microbiology and biotechnology
Dabrafenib, an inhibitor of mutated BRAF , has significant clinical activity in melanoma patients but is linked to a spectrum of cutaneous toxicities. Thus, our meta-analysis was conducted to evaluate the type, incidence and risks of dermatological toxicities from dabrafenib.